stockportfolio.pro
Stocks / BLFS vs INBX
BLFS vs INBX
BioLife Solutions, Inc. and Inhibrx Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BioLife Solutions, Inc. (BLFS) | Inhibrx Biosciences, Inc. (INBX) | |
|---|---|---|
| Market cap | $1.3B | $1.3B |
| Revenue (latest FY) | $96.21M | $1.30M |
| Net income (latest FY) | $-4.59M | $-140.06M |
| Revenue growth (5y CAGR) | 14.9% | -0.0% |
| Net margin | -4.8% | -10773.5% |
| Return on equity | -1.2% | -1752.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BLFS — free Open INBX — freeFrequently asked questions
Which is bigger, BLFS or INBX?
Inhibrx Biosciences, Inc. is larger by market capitalization — $1.3B versus $1.3B.
Which grows faster, BLFS or INBX?
Over the last five fiscal years, BioLife Solutions, Inc. grew revenue faster — 14.9%/yr versus -0.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.